Table 3 Efficacy of Tepotinib in VISION trial
From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
|  | Patients with METex14 skipping mutation (efficacy population: n = 99) | ||
|---|---|---|---|
Liquid biopsy (n = 66) | Tissue biopsy (n = 60) | Combined biopsy (n = 99) | |
ORR (%) | 48 (95% CI: 36–61) | 50 (95% CI: 37–63) | 46 (95% CI: 36–57) |
Medium DOR (mo) | 9.9 (95% CI: 72–NE) | 15.7 (95% CI: 9.7–NE) | 11 (95% CI: 7.2–NE) |
Medium PFS (mo) | 8.5 (95% CI: 5.1–11.0) | 11.0 (95% CI: 5.7–17.1) | 8.5 (95% CI: 6.7–11.0) |
| Â | Patients with brain metastasis (n-11) |
|---|---|
ORR (%) | 55 (95% CI: 23–83) |
DOR (mo) | 9.5 (95% CI: 6.6–NE) |
PFS (mo) | 10.9 (95% CI: 8.0–NE) |